Clinical Trial

Pilot Study to Evaluate Efficacy and Safety of Switching to BIC/FTC/TAF in PWH With a Previous Virological Failure Under CAB/RPV LAI

Study acronym: BICPREVIR
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study is a pilot, multi-center, observational retrospective-prospective study, with two different Parts, as follows: 1. Part 1(retrospective and prospective part): to evaluate efficacy and safety of switching to BIC/FTC/TAF in People living with HIV (PWH) who previously failed CAB/RPV LAI in the last three years and received in the last three years boosted PI since any INSTI mutations were detected on RNA and/or DNA through NGS at failure 2. Part 2 (prospective part only): to evaluate efficacy and safety of switching directly to BIC/FTC/TAF in PWH who failed CAB/RPV LAI without any RAMs on RNA and/or DNA through NGS considered of potential relevance for bictegravir Inclusion Criteria: * PWH with age \>18 years * PWH with a confirmed virological failure on CAB/RPV LAI in the last three years * PWH without RAMs versus FTC and TAF Study population: 30 subjects failing CAB/RPV LAI will be included in the study
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-26.
Trial Details
NCT Number NCT07620652
Lead Sponsor Cristina Mussini
Conditions HIV Infection
Enrollment 30 participants
Start Date 2026-07
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-07